The first patients in the UK have now received an innovative theranostics treatment for advanced prostate cancer at GenesisCare, giving new hope for men who have exhausted other treatment options. The UK’s largest private cancer care provider, GenesisCare, announced today that the service is now available at its centre in Windsor for the first time in the UK.
This press release features multimedia.
Theranostics is a highly personalised approach to cancer medicine that combines two techniques in one: diagnostic (imaging) and therapy. The diagnostic approach uses a radioactive tracer that is specific to receptors found on the surface of cancer cells. 1 The therapy ( 177 Lutetium PSMA) is equally specific and targets the same protein receptors on the prostate cancer cells. The radioactive tracer acts like a ‘smart homing missile’ to locate and destroy cancer cells. The targeted therapy limits damage to surrounding normal cells, to minimise potential side effects and improve a patient’s quality of life. 2
“Prostate cancer is the most common cancer among men, yet treatment options which extend survival and provide hope for a good quality of life remain limited in late stage disease,” said Dr Yong Du, UK Clinical Director – Theranostics at GenesisCare. “While not a complete cure, theranostics can enable suitable patients a good quality of life, for longer, and I am proud to be part of bringing this new and highly innovative technique to the UK – something that patients in Germany and Australia have been able to access for a number of years already.”
Theranostics can be used to treat areas where cancer has spread, or if cancer is advanced and has not responded to other treatments. There are limited options for patients with late-stage prostate cancer, with many men having exhausted their treatment options or are left unable to tolerate current treatments.
“Prostate cancer in its late stages remains a leading cause of death in men, 3 ” said Dr Richard Shaffer, Clinical Oncologist at GenesisCare. “Innovative, accessible options that improve quality of life, such as theranostics, are required in advanced prostate cancer and I hope to see greater access to these kinds of cutting-edge treatments.”
“GenesisCare aims to provide the best possible outcomes for our patients. The introduction of the first clinically available theranostics programme in the UK reinforces our commitment, and furthers our goal of bringing innovative, holistic solutions to cancer patients in the UK,” said Emma Spellman, Head of Theranostics and Imaging at GenesisCare UK.
The GenesisCare centre in Windsor is now offering theranostics for advanced prostate cancer and all neuroendocrine tumours, including head and neck cancers and gastrointestinal cancers, with the first four patients in the UK now treated. For further information, please visit www.genesiscare.com/uk